pd 98059 has been researched along with Acute Myelogenous Leukemia in 11 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leptin acts as a growth factor in normal cells as well as in various types of cancer cells." | 5.36 | Molecular mechanisms of cellular proliferation in acute myelogenous leukemia by leptin. ( Choi, JH; Kim, BK; Kim, ES; Kim, JY; Kim, SJ; Lee, YY; Park, BB; Park, HK; Song, SH; Yoon, JS, 2010) |
| "Cells derived from acute myelogenous leukemia (AML) are used as our model system." | 5.32 | Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. ( Khosravi, F; Minden, MD; Penn, LZ; Wong, WW; Wu, J, 2004) |
| "Leptin acts as a growth factor in normal cells as well as in various types of cancer cells." | 1.36 | Molecular mechanisms of cellular proliferation in acute myelogenous leukemia by leptin. ( Choi, JH; Kim, BK; Kim, ES; Kim, JY; Kim, SJ; Lee, YY; Park, BB; Park, HK; Song, SH; Yoon, JS, 2010) |
| "Cells derived from acute myelogenous leukemia (AML) are used as our model system." | 1.32 | Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. ( Khosravi, F; Minden, MD; Penn, LZ; Wong, WW; Wu, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Li, Z | 1 |
| Song, T | 1 |
| Xue, Z | 1 |
| Zhang, Z | 1 |
| Xu, H | 1 |
| Li, Y | 1 |
| Chen, L | 1 |
| Wang, C | 1 |
| Wang, Q | 1 |
| Zhang, H | 1 |
| Lin, Y | 1 |
| Li, Q | 1 |
| Pang, T | 1 |
| Kim, JY | 1 |
| Park, HK | 1 |
| Yoon, JS | 1 |
| Kim, SJ | 1 |
| Kim, ES | 1 |
| Song, SH | 1 |
| Choi, JH | 1 |
| Kim, BK | 1 |
| Park, BB | 1 |
| Lee, YY | 1 |
| Hampson, P | 1 |
| Wang, K | 1 |
| Milverton, L | 1 |
| Ersvaer, E | 1 |
| Bruserud, O | 1 |
| Lord, JM | 1 |
| Zhang, T | 1 |
| He, YM | 1 |
| Wang, JS | 1 |
| Shen, J | 1 |
| Xing, YY | 1 |
| Xi, T | 1 |
| Zhou, X | 1 |
| Fang, Y | 1 |
| Jing, H | 1 |
| Zhong, L | 1 |
| Luo, P | 1 |
| Song, H | 1 |
| Yang, B | 1 |
| He, Q | 1 |
| Lunghi, P | 1 |
| Tabilio, A | 1 |
| Dall'Aglio, PP | 1 |
| Ridolo, E | 1 |
| Carlo-Stella, C | 1 |
| Pelicci, PG | 1 |
| Bonati, A | 1 |
| Wu, J | 1 |
| Wong, WW | 1 |
| Khosravi, F | 1 |
| Minden, MD | 1 |
| Penn, LZ | 1 |
| Rovida, E | 1 |
| Gozzini, A | 1 |
| Barbetti, V | 1 |
| Giuntoli, S | 1 |
| Santini, V | 1 |
| Dello Sbarba, P | 1 |
| Kojima, K | 1 |
| Konopleva, M | 2 |
| Samudio, IJ | 1 |
| Ruvolo, V | 1 |
| Andreeff, M | 2 |
| Milella, M | 1 |
| Kornblau, SM | 1 |
| Estrov, Z | 1 |
| Carter, BZ | 1 |
| Lapillonne, H | 1 |
| Harris, D | 1 |
| Zhao, S | 1 |
| Estey, E | 1 |
11 other studies available for pd 98059 and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Mechanisms of anti-leukemic activity of the Bcl-2 homology domain-3 mimetic S1.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associat | 2013 |
SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway.
Topics: Adolescent; Adult; Aged; Apoptosis; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Mult | 2016 |
Molecular mechanisms of cellular proliferation in acute myelogenous leukemia by leptin.
Topics: Cell Proliferation; Flavonoids; HL-60 Cells; Humans; K562 Cells; Leptin; Leukemia, Myeloid, Acute; M | 2010 |
Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).
Topics: Animals; Antineoplastic Agents; Apoptosis; Diterpenes; Enzyme Activation; Enzyme Inhibitors; Flavono | 2010 |
Ursolic acid induces HL60 monocytic differentiation and upregulates C/EBPβ expression by ERK pathway activation.
Topics: Antineoplastic Agents, Phytogenic; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Cell G | 2011 |
Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferatio | 2013 |
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts.
Topics: Adult; Aged; Apoptosis; Caspases; Cell Differentiation; Cell Division; Cells, Cultured; Down-Regulat | 2003 |
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Down-Regulation; Flavonoids; Humans; Leukemia, Myeloid, Acute; Lov | 2004 |
The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells.
Topics: Anthracenes; Apoptosis; Blotting, Western; Butyrates; Caspase 8; Cell Line, Tumor; Chromosomes, Huma | 2006 |
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Nucleus; Drug Synergism; Fatty Acids, Unsaturated; Flavonoids; Hum | 2007 |
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhib | 2001 |